Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus

Emerging Infectious Diseases

Volumn 22, Issue 7, 2016, Pages E1-E11

  Uyeki, Timothy M ^a   Erlandson, Karl J ^b   Korch, George ^b   O'Hara, Michael ^b   Wathen, Michael ^b   Hu Primmer, Jean ^b   Hojvat, Sally ^c   Stemmy, Erik J ^d   Donabedian, Armen ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Office of the Assistant Secretary for Preparedness and Response   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CAMEL; CLINICAL TRIAL (TOPIC); CLINICAL TRIAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE TRANSMISSION; EFFICACY PARAMETERS; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMORAL IMMUNITY; MEDICAL COUNTERMEASURE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PUBLIC HEALTH SERVICE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAFETY; SARS CORONAVIRUS; SAUDI ARABIA; SOUTH KOREA; UNITED STATES; VACCINATION; ZIKA FEVER; ANIMAL; CORONAVIRUS INFECTION; DISEASE MODEL; IMMUNOLOGY; VETERINARY; VIROLOGY;

ANIMALS; CAMELUS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VIRAL VACCINES;

EID: 85017301680     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/EID2207.160022     Document Type: Article

References (85)

1. World Health Organization. Emergencies preparedness, response: Middle East respiratory syndrome coronavirus (MERS-CoV)-Saudi Arabia. 2016 Apr 27 [cited 2016 Apr 27]. http://www.who.int/csr/don/26-april-2016-mers-saudi-arabia/en/
2. World Health Organization. Summary of current situation, literature update and risk assessment [updated 2015 July 7; cited 2015 Aug 12]. http://apps.who.int//iris/bitstream/10665/179184/2/WHO_MERS_RA_15.1_eng.pdf
3. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DAT, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407-16. http://dx.doi.org/10.1056/NEJMoa1306742
4. Oboho IK, Tomczyk SM, Al-Asmari AM, Banjar AA, Al-Mugti H, Aloraini MS, et al. 2014 MERS-CoV outbreak in Jeddah-a link to health care facilities. N Engl J Med. 2015;372:846-54. http://dx.doi.org/10.1056/NEJMoa1408636
5. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis. 2016;22:49-55. Epub 2015 Dec 18.
6. Bin SY, Heo JY, Song MS, Lee J, Kim EH, Park SJ, et al. Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea. Clin Infect Dis. 2016;62:755-60. http://dx.doi.org/10.1093/cid/civ1020
7. Bialek SR, Allen D, Alvarado-Ramy F, Arthur R, Balajee A, Bell D, et al. First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities-May 2014. MMWR Morb Mortal Wkly Rep. 2014;63:431-6.
8. Kapoor M, Pringle K, Kumar A, Dearth S, Liu L, Lovchik J, et al. Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States. Clin Infect Dis. 2014;59:1511-8. http://dx.doi.org/10.1093/cid/ciu635
9. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)-Republic of Korea. 2015 Jul 21 [cited 2016 Jan 5]. http://www.who.int/csr/don/21-july-2015-mers-korea/en/
10. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)-China. 2015 May 30 [cited 2015 Dec 21]. http://www.who.int/csr/don/30-may-2015-mers-china/en/
11. National Institutes of Health. Middle East respiratory syndrome coronavirus (MERS-CoV) research: current status and future priorities. 2013 Jun 24 [cited 2015 Dec 1]. http://www.niaid.nih.gov/about/organization/dmid/documents/mers-covmeeting.pdf
12. National Academies of Sciences, Engineering, and Medicine. 2016. Rapid medical countermeasure response to infectious diseases: enabling sustainable capabilities through ongoing public and private-sector partnerships. Workshop summary [cited 2016 Mar 17]. http://www.nap.edu/read/21809/chapter/1
13. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111:4970-5. http://dx.doi.org/10.1073/pnas.1323279111
14. Agrawal AS, Garron T, Tao X, Peng B-H, Wakamiya M, Chan T-S, et al. Generation of transgenic mouse model of Middle East respiratory syndrome-coronavirus infection and disease. J Virol. 2015 Jan 14;JVI.03427-14. http://dx.doi.org/10.1128/JVI.03427-14
15. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2015;213:8738-43 http://dx.doi.org10.1073/pnas.1510830112
16. Houser KV, Gretebeck L, Ying T, Wang Y, Vogel L, Lamirande EW, et al. Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. J Infect Dis. Epub 2016 Mar 3. http://dx.doi.org/10.1093/infdis/jiw080
17. de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110:16598-603. http://dx.doi.org/10.1073/pnas.1310744110
18. Falzarano D, de Wit E, Feldmann F, Rasmussen AL, Okumura A, Peng X, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10:e1004250. http://dx.doi.org/10.1371/journal.ppat.1004250
19. Adney DR, van Doremalen N, Brown VR, Bushmaker T, Scott D, de Wit E, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis. 2014;20:1999-2005. http://dx.doi.org/10.3201/eid2012.141280
20. Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol. 2015;13:123-9. http://dx.doi.org/10.1016/j.coviro.2015.06.009
21. Baseler L, de Wit E, Feldmann H. A comparative review of animal models of Middle East respiratory syndrome coronavirus infection. Vet Pathol. Epub 2016 Feb 11. http://dx.doi.org/10.1177/0300985815620845
22. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2015;112:8738-43. http://dx.doi.org/10.1073/pnas.1510830112
23. van Doremalen N, Munster VJ. Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res. 2015;22:28-38. Epub 2015 Jul 16.
24. Chan JFW, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset. J Infect Dis. 2015;212:1904-13. http://dx.doi.org/10.1093/infdis/jiv392
25. Johnson RF, Via LE, Kumar MR, Cornish JP, Yellayi S, Huzella L, et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology. 2015;485:422-30. http://dx.doi.org/10.1016/j.virol.2015.07.013
26. Adney D, Bielefeldt-Ohmann H, Hartwig A, Bowen RA. Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas. Emerg Infect Dis. 2016 Jun. Epub 2016 Mar 4. http://dx.doi.org/10.3201/eid2206.160192
27. Crameri G, Durr PA, Klein R, Foord A, Yu M, Riddell S. Experimental infection and response to rechallenge of alpacas with Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016 Jun. Epub 2016 Mar 7. http://dx.doi.org/10.3201/eid2206.160007
28. Reusken CBEM, Schilp C, Raj VS, De Bruin E, Kohl RHG, Farag EABA, et al. MERS-CoV infection of alpaca in a region where MERS-CoV is endemic [letter]. Emerg Infect Dis. 2016 Jun. Epub 2016 Feb 16. http://dx.doi.org/10.3201/eid2206.152113
29. Song JY, Cheong HJ, Choi MJ, Jeon JH, Kang SH, Jeong EJ, et al. Viral shedding and environmental cleaning in Middle East respiratory syndrome coronavirus infection. Infect Chemother. 2015;47:252-5. http://dx.doi.org/10.3947/ic.2015.47.4.252
30. Memish ZA, Assiri AM, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications. Int J Infect Dis. 2014;29:307-8. http://dx.doi.org/10.1016/j.ijid.2014.10.002
31. Office of the Commissioner. MCM Legal, Regulatory and Policy Framework-Emergency Use Authorization; Middle East respiratory syndrome coronavirus (MERS-VoV) EUS information [cited 2015 Oct 1]. http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatory andPolicyFramework/ucm182568.htm#MERS
32. Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill. 2012; 17:20334.
33. Pas SD, Patel P, Reusken C, Domingo C, Corman VM, Drosten C, et al. First international external quality assessment of molecular diagnostics for Mers-CoV. J Clin Virol. 2015;69:81-5. http://dx.doi.org/10.1016/j.jcv.2015.05.022
34. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014; 58:4875-84. Epub 2014 May 19.
35. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58:4885-93. http://dx.doi.org/10.1128/AAC.03036-14
36. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19:1313-7. http://dx.doi.org/10.1038/nm.3362
37. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42-6. http://dx.doi.org/10.1016/j.ijid.2013.12.003
38. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14:1090-5. http://dx.doi.org/10.1016/S1473-3099(14)70920-X
39. European Medicines Agency. Public summary of opinion on orphan designation. Interferon alfa-n3 for the treatment of Middle East respiratory syndrome. 5 Jan 2016 [cited 2016 Mar 17]. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2016/01/WC500199406.pdf
40. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. 2006;3:e343. http://dx.doi.org/10.1371/journal.pmed.0030343
41. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508:402-5. http://dx.doi.org/10.1038/nature13027
42. Adedeji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR, et al. Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses. Antimicrob Agents Chemother. Epub 2014 May 19 [cited 2014 May 22]. http://aac.asm.org/cgi/doi/10.1128/AAC.02994-14
43. Wycoff K, Maclean J, Belle A, Yu L, Tran Y, Roy C, et al. Anti-infective immunoadhesins from plants. Plant Biotechnol J. 2015;13:1078-93. http://dx.doi.org/10.1111/pbi.12441
44. Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, et al. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis. 2015;212:1894-903. http://dx.doi.org/10.1093/infdis/jiv325
45. Kilianski A, Mielech AM, Deng X, Baker SC. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based bio-sensors. J Virol. 2013;87:11955-62. http://dx.doi.org/10.1128/JVI.02105-13
46. ClinicalTrials.gov. Anti-MERS-COV convalescent plasma therapy [cited 2015 Aug 11]. https://clinicaltrials.gov/ct2/show/NCT02190799
47. Shultz D. Cows with human chromosomes enlisted to fight hantavirus. Science. Epub 2014 Nov 25 [cited 2015 Aug 11. http://news.sciencemag.org/biology/2014/11/cows-human-chromosomes-enlisted-fight-hantavirus
48. Ying T, Du L, Ju TW, Prabakaran P, Lau CCY, Lu L, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014;88:7798-7806. http://dx.doi.org/10.1128/JVI.00912-14
49. Jiang L, Wang N, Zuo T, Shi X, Poon KMV, Wu Y, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6:234ra59. http://dx.doi.org/10.1126/scitranslmed
50. Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A. 2014;111:E2018-26. http://dx.doi.org/10.1073/pnas.1402074111
51. Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in MERS-CoV spike protein. J Virol. 2014;88:7045-53. http://dx.doi.org/10/1128/JVI.00433-14
52. Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013; 87:13892-9. http://dx.doi.org/10.1128/JVI.02448-13
53. Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA. 2015;112:10473-8. http://dx.doi.org/10.1073/pnas.1510199112
54. Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov. Epub 2016 Feb 12. http://dx.doi.org/10.1038/nrd.2015.37
55. Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology. 2016;490:49-58. http://dx.doi.org/10.1016/j.virol.2016.01.004
56. Ying T, Li H, Lu L, Dimitrov DS, Jiang S. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect. 2015;17:142-8. http://dx.doi.org/10.1016/j.micinf.2014.11.008
57. Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, et al. Human polyclonal immunoglobulin G from transchromo-somic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016;8:326. http://dx.doi.org/10.1126/scitranslmed.aaf1061
58. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160:389-97. http://dx.doi.org/10.7326/M13-2486
59. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712. http://dx.doi.org/10.1038/ncomms8712
60. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7:301ra132. http://dx.doi.org/10.1126/scitranslmed.aac7462
61. Clinical Trials.gov. Phase I, open label dose ranging safety study of GLS-5300 in healthy volunteers [cited 2016 Mar 17]. https://clinicaltrials.gov/ct2/show/NCT02670187?term=mers-cov&rank=7
62. Greffex, Inc. MERS [cited 2015 Oct 1]. http://www.greffex.com/vaccines/mers/
63. Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol. 2013;87:11950-4. http://dx.doi.org/10.1128/JVI.01672-13
64. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol. 2015;89:8651-6. http://dx.doi.org/10.1128/JVI.00614-15
65. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712. http://dx.doi.org/10.1038/ncomms8712
66. Almazan F, DeDiego ML, Sola I, Zuniga S, Nieto-Torres JL, Marquez-Jurado S, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBiol 2013;4:e00650-13. http://dx.doi.org/10.1128/mBio.00650-13
67. Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016;13:180-90. http://dx.doi.org/10.1038/cmi.2015.03
68. Agnihothram S, Gopal R, Yount BL, Donaldson EF, Menachery VD, Graham RL, et al. Evaluation of serologic and antigenic relationships between Middle Eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis. 2014;209:995-1006. http://dx.doi.org/10.1093/infdis/jit609
69. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. 2012;7:e35421. http://dx.doi.org/10.1371/journal.pone.0035421
70. Dodge J. Camels emit dangerous MERS virus, CSU confirms. November 2014 [cited 2015 Oct 2]. http://source.colostate.edu/camels-emit-mers/
71. Kupferschmidt K. MERS surges again, but pandemic jitters ease. Science. 2015;347:1296-7. http://dx.doi.org/10.1126/science.347.6228.1296
72. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32:5975-82. http://dx.doi.org/10.1016/j.vaccine.2014.08.058
73. Khalafalla AI, Lu X, Al-Mubarak AIA, Dalab AHS, Al-Busadah KAS, Erdman DD. MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg Infect Dis. 2015;21:1153-8. http://dx.doi.org/10.3201/eid2107.150070
74. Hemida MG, Chu DKW, Poon LLM, Perera RAPM, Alhammadi MA, Ng H, et al. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis. 2014;20:1231-4. http://dx.doi.org/10.3201/eid2007.140571
75. Meyer B, Juhasz J, Barua R, Das Gupta A, Hakimuddin F, Corman VM, et al. Time course of MERS-CoV infection and immunity in dromedary camels. Emerg Infect Dis. 2016 Dec [cited 2016 June 3]. http://dx.doi.org/10.3201/eid2212.160382
76. Farag EA, Reusken CB, Haagmans BL, Mohran KA, Raj V, Pas SD, et al. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infect Ecol Epidemiol. 2015;5:28305.
77. Haagmans BL, van den Brand JMA, Raj VS, Volz A, Wohlsein P, Smits SL, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351:77-81. http://dx.doi.org/10.1126/science.aad1283
78. Food and Drug Administration. Guidances (Drugs) [cited 2015 Aug 11]. http://www.fda.gov/Drugs/GuidancecomplianceRegulatoryInformation/Guidances/default.htm
79. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301-6. http://dx.doi.org/10.1016/j.ijid.2014.09.003
80. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752-61. http://dx.doi.org/10.1016/S1473-3099(13)70204-4
81. Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in United Arab Emirates, April 2014. Am J Pathol. 2016;186:652-8. Epub 2016 Feb 5. http://dx.doi. org/10.1016/j.ajpath.2015.10.024
82. Chu H, Zhou J, Wong BHY, Li C, Chan JFW, Cheng ZS, et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis. 2016;904-14. http:10.1093/infdis/jiv380
83. International Severe Acute Respiratory and Emerging Infection Consortium. Severe acute respiratory infection data tools [cited 2015 Aug 11]. https://isaric.tghn.org/protocols/severe-acuterespiratory-infection-data-tools/
84. Dunning JW, Merson L, Rohde GGU, Gao Z, Semple MG, Tran D, et al. Open source clinical science for emerging infections. Lancet Infect Dis. 2014;14:8-9 and.
85. World Health Organization. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected. Interim guidance. Updated 2 July 2015 [cited 2015 Aug 11]. http://apps.who.int/iris/bitstream/10665/178529/1/WHO_MERS_Clinical_15.1_eng.pdf